Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GPCR

3 Companies at the Forefront of the GLP-1 Pill Wars

The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

2 ‘Monster’ Stocks to Snap Up Before 2025

2 ‘Monster’ Stocks to Snap Up Before 2025

Analysts at Jefferies have identified Metagenomi and Structure Therapeutics as two "monster" stocks in the biotech sector, with potential gains of up to 1,000%.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?

With weight-loss drugs gaining traction, which biopharma stock wins?

JPMorgan Forecast Over 85% Upside for Two Biopharma Stocks Targeting Obesity and Chronic Conditions

The two biopharma firms have developed drug candidates to treat autoimmune and pulmonary diseases. They have demonstrated good safety profiles and efficacy in various stages of clinical trials.

International Business Times UK

This Weight-Loss Stock Could Surge 75%, Says JPMorgan

Structure Therapeutics is a clinical-stage weight-loss company that is poised to gain traction in a rapidly expanding addressable market.

inkl

Read news from The Economist, FT, and more,
with one subscription

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

People

174,287 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Viking Therapeutics

Viking Therapeutics Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

352,338 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play